Target intelligence / Profile preview

Cytochrome P450 7A1 (CYP7A1) (CYP7A1)

Target
CYP7A1
Molecular classification
Enzyme, Cytochrome P450, Monooxygenase, Oxidoreductase
01

Overview

Cytochrome P450 7A1 (CYP7A1), also known as cholesterol 7-alpha-hydroxylase, is a liver-specific microsomal enzyme that catalyzes the rate-limiting step in the classic pathway of bile acid synthesis from cholesterol. By converting cholesterol into 7-alpha-hydroxycholesterol, CYP7A1 plays a critical role in maintaining systemic cholesterol homeostasis and represents the primary pathway for cholesterol elimination from the body. Dysregulation or genetic deficiency of CYP7A1 is strongly associated with hypercholesterolemia, premature gallstone disease, nonalcoholic fatty liver disease (NAFLD), and an increased risk of coronary artery disease. While there are few direct pharmacological inhibitors or activators of CYP7A1 in clinical use, its activity is highly regulated by feedback mechanisms involving nuclear receptors like the farnesoid X receptor (FXR) and the pregnane X receptor (PXR). Consequently, drugs such as FXR agonists (e.g., obeticholic acid), bile acid sequestrants (e.g., cholestyramine), and ASBT inhibitors (e.g., linerixibat) are used to indirectly modulate CYP7A1 expression and activity to treat lipid and cholestatic disorders.

Other names
Cholesterol 7-alpha-hydroxylaseCholesterol 7-alpha-monooxygenase24-hydroxycholesterol 7-alpha-hydroxylaseCYPVIICytochrome P450, family 7, subfamily A, polypeptide 1
02

Mechanism of action

Drugs targeting or modulating CYP7A1 typically act indirectly. This includes farnesoid X receptor (FXR) agonists that repress CYP7A1 expression, bile acid sequestrants and ASBT inhibitors that relieve feedback inhibition to upregulate CYP7A1, and PXR agonists that downregulate its transcription. Direct enzymatic inhibitors are primarily experimental.

03

Biological functions

Bile acid biosynthetic processCholesterol catabolic processCholesterol homeostasisOxidation of cholesterolLipid metabolism
04

Disease associations

HypercholesterolemiaNonalcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)Coronary artery diseaseGallstone diseaseDyslipidemiaCardiovascular disease
05

Safety considerations

Hepatotoxicity and drug-induced liver injury (DILI) due to accumulation of toxic bile acidsDisruption of cholesterol and bile acid homeostasisGallstone formation (cholelithiasis)Impaired absorption of fat-soluble vitaminsGastrointestinal side effects (e.g., diarrhea, constipation)Increased risk of cardiovascular disease if CYP7A1 is deficient or inhibited
06

Interacting drugs

12 more in the full profile.

07

Biomarkers

7alpha-hydroxy-4-cholesten-3-one (C4)CYP7A1 mRNA expressionCYP7A1 protein levelsLow-density lipoprotein cholesterol (LDL-C)Total cholesterolBile acid levelsCYP7A1 single nucleotide polymorphisms (e.g., rs3808607, rs9297994, rs10504255)

Beyond the preview

Go deeper on Cytochrome P450 7A1 (CYP7A1) (CYP7A1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome P450 7A1 (CYP7A1) (CYP7A1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call